natgillin/translations-raw huggingface dataset:
Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section phosphatase increased (see section 4.4)
Odpoved delovanja jeter (glejte poglavje 4.4), nekroza jetrnih celic (glejte poglavje 4.4), hepatitis (glejte poglavje 4.4), poškodba jetrnih celic (glejte poglavje 4.4)
Titanium dioxide (E171) Patent blue V (E131)
150 mg kapsule želatina titanov dioksid (E171) patentno modro barvilo V (E131)
NAME OF THE MEDICINAL PRODUCT Diflucan and associated names (see Annex I) 40 mg/ml powder for oral suspension [See Annex I - To be completed nationally]
Diflucan in povezana imena (glejte Prilogo I) 40 mg/ml prašek za peroralno suspenzijo [glejte Prilogo I - izpolni država članica]
1 bottle - 35 ml suspension after reconstitution
FARMACEVTSKA OBLIKA IN VSEBINA prašek za peroralno suspenzijo 1 plastenka - 35 ml suspenzije po rekonstituciji
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains fluconazole 150 mg.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena trda kapsula vsebuje 150 mg flukonazola.
NAME OF THE MEDICINAL PRODUCT Diflucan and associated names (see Annex I) 2 mg/ ml solution for infusion [See Annex I - To be completed nationally] Fluconazole
Diflucan in povezana imena (glejte dodatek I) 2 mg/ml raztopina za infundiranje [glejte dodatek I - Izpolni država članica] flukonazol
They have “FLU-150” and “Pfizer” with black ink printed on them.
Na obeh je s črnilom črne barve natisnjeno "FLU-150" in "Pfizer".
(Powder for oral suspension (175 ml bottle): Store below 25°C.
Prašek za peroralno suspenzijo (175 ml plastenka): Shranjujte pri temperaturi do 25 °C.
- rifampicin or rifabutin (antibiotics for infections) - alfentanil, fentanyl (used as anaesthetic) - amitriptyline, nortriptyline (used as anti-depressant) - amphotericin B, voriconazole (anti-fungal) - medicines that thin the blood to prevent blood clots (warfarin or similar medicines) - benzodiazepines (midazolam, triazolam or similar medicines) used to help you sleep or for anxiety - carbamazepine, phenytoin (used for treating fits) - nifedipine, isradipine, amlodipine felodipine and losartan (for hypertension- high blood pressure) - ciclosporin, everolimus, sirolimus or tacrolimus (to prevent transplant rejection) - cyclosphosphamide, vinca alkaloids (vincristine, vinblastine or similar medicines) used for treating cancer - halofantrine (used for treating malaria) - statins (atorvastatin, simvastatin and fluvastatin or similar medicines) used for reducing high cholesterol levels - methadone (used for pain) - celecoxib, flurbiprofen, naproxen, ibuprofen, lornoxicam, meloxicam, diclofenac
- rifampicin ali rifabutin (antibiotika za zdravljenje okužb) - alfentanil, fentanil (uporabljata se kot anestetika) - amitriptilin, nortriptilin (uporabljata se kot antidepresiva) - amfotericin B, vorikonazol (protiglivični zdravili) - zdravila, ki redčijo kri, da preprečijo nastajanje krvnih strdkov (varfarin ali podobna zdravila) - benzodiazepini (midazolam, triazolam ali podobna zdravila), ki se uporabljajo kot uspavala ali za zdravljenje tesnobe - karbamazepin, fenitoin (uporabljata se za zdravljenje konvulzij (napadi podobni epileptičnim)) - nifedipin, isradipin, amlodipin, felodipin in losartan (za zdravljenje hipertenzije - visokega krvnega tlaka) - ciklosporin, everolimus, sirolimus ali takrolimus (za preprečevanje zavrnitve presajenih organov) - ciklofosfamid, alkaloidi vinke (vinkristin, vinblastin ali podobna zdravila), ki se uporabljajo za zdravljenje rakavih obolenj - halofantrin (uporablja se za zdravljenje malarije) - statini (atorvastatin, simvastatin in fluvastatin ali podobna zdravila), ki se uporabljajo pri zdravljenju visokih ravni holesterola - metadon (uporablja se pri bolečinah) - celekoksib, flurbiprofen, naproksen, ibuprofen, lornoksikam, meloksikam, diklofenak
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml of reconstituted suspension contains 10 mg fluconazole.
KAKOVOSTNA IN KOLIČINSKA SESTAVA 1 ml za uporabo pripravljene (rekonstituirane) suspenzije vsebuje 10 mg flukonazola.
HOW TO TAKE DIFLUCAN Always take your medicine exactly as your doctor has told you.
Pri jemanju zdravila Diflucan natančno upoštevajte zdravnikova navodila.
Diflucan is supplied as a solution.
Zdravilo Diflucan je na voljo v obliki raztopine.
You might also be given Diflucan to: - stop cryptococcal meningitis from coming back - stop mucosal trush from coming back - stop you from getting an infection caused by Candida (if your immune system is weak and not working properly)
- da bi preprečili ponovitev kriptokoknega meningitisa - da bi preprečili ponovitev okužbe sluznic - da bi preprečili, da bi pri vas prišlo do okužbe, ki jo povzroča kandida (v primeru, da je vaš imunski sistem oslabljen in ne deluje ustrezno)
This leaflet was last approved in
Navodilo je bilo odobreno:
NAME OF THE MEDICINAL PRODUCT Diflucan and associated names (see Annex I) 5 mg/ml oral solution [See Annex I - To be completed nationally]
Diflucan in povezana imena (glejte Dodatek I) 5 mg/ml peroralna raztopina [glejte Dodatek I - Izpolni država članica]
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml of reconstituted suspension contains 40 mg fluconazole.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN 1 ml rekonstituirane suspenzije vsebuje 40 mg flukonazola.
SPECIAL STORAGE CONDITIONS Powder for oral suspension (60 ml bottle): Store below 25°C Powder for oral suspension (175 ml bottle): Store below 25°C.
Prašek za peroralno suspenzijo (60 ml plastenka): Shranjujte pri temperaturi do 25 °C.
The 200 mg hard gelatin capsule has a white body and a purple cap overprinted with “Pfizer” and the code “FLU-200” with black ink.
Velikost kapsule je št. 1. 200 mg trda želatinska kapsula ima belo telo in vijoličasto kapico, na obeh pa je s črnilom črne barve natisnjena oznaka "Pfizer" in šifra "FLU-200".
NAME OF THE MEDICINAL PRODUCT Diflucan and associated names (see Annex I) 2 mg/ml solution for infusion [See Annex I - To be completed nationally]
Diflucan in povezana imena (glejte Dodatek I) 2 mg/ml raztopina za infundiranje [glejte Dodatek I - Izpolni država članica]
PACKAGE LEAFLET: INFORMATION FOR THE USER Diflucan and associated names (see Annex I) 5 mg/ml oral solution [See Annex I - To be completed nationally] fluconazole
NAVODILO ZA UPORABO Diflucan in povezana imena (glejte Dodatek I) 5 mg /ml peroralna raztopina [glejte Dodatek I - Izpolni država članica] flukonazol
They have “FLU-50” and “Pfizer” with black ink printed on them.
Na obeh je s črnilom črne barve natisnjeno "FLU-50" in "Pfizer".
Seizures, paraesthesia, dizziness, taste perversion
Tremor podobni epileptičnim), parestezija, omotica, motnje v zaznavanju okusa
Coadministration of fluconazole and quinidine is contraindicated (see section 4.3).
Sočasna uporaba flukonazola in kinidina je kontraindicirana (glejte poglavje 4.3).
PHARMACEUTICAL FORM AND CONTENTS Oral solution
FARMACEVTSKA OBLIKA IN VSEBINA peroralna raztopina
NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION Diflucan and associated names (see Annex I) 2 mg/ ml solution for infusion [See Annex I - To be completed nationally]
IME ZDRAVILA IN POT UPORABE ZDRAVILA Diflucan in povezana imena (glejte Prilogo I) 2 mg/ml raztopina za infundiranje [glejte Prilogo I - izpolni država članica] flukonazol intravenska uporaba
Diflucan and associated names (see Annex I) 50 mg capsules Diflucan and associated names (see Annex I) 100 mg capsules Diflucan and associated names (see Annex I) 150 mg capsules Diflucan and associated names (see Annex I) 200 mg capsules [See Annex I - To be completed nationally] fluconazole
Diflucan in povezana imena (glejte Dodatek I) 50 mg trde kapsule Diflucan in povezana imena (glejte Dodatek I) 100 mg trde kapsule Diflucan in povezana imena (glejte Dodatek I) 150 mg trde kapsule Diflucan in povezana imena (glejte Dodatek I) 200 mg trde kapsule [glejte dodatek I - Izpolni država članica] flukonazol
The 100 mg hard gelatin capsule has a white body and blue cap overprinted with “Pfizer” and the code “FLU-100” with black ink.
Velikost kapsule je št. 4. 100 mg trda želatinska kapsula ima belo telo in modro kapico, na obeh pa je s črnilom črne barve natisnjena oznaka "Pfizer" in šifra "FLU-100".
They have “FLU-100” and “Pfizer” with black ink printed on them.
Na obeh je s črnilom črne barve natisnjeno "FLU-100" in "Pfizer".
BATCH NUMBERS
ATC klasifikacija
Constipation disorders vomiting, diarrhoea, nausea dyspepsia, flatulence, dry mouth
spremembe v zaznavanju okusa - zaprtje, težave s prebavo, vetrovi, suha usta
You might be given this medicine by your doctor to treat the following types of fungal infections: - Mucosal thrush - infection affecting the lining of the mouth, throat - Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract - Cryptococcal meningitis - a fungal infection in the brain
- Glivična okužba sluznice - okužbo ustne sluznice ali grla - Okužbe, povzročene s kandido, ugotovljene v krvnem obtoku, telesnih organih (npr. srce,
Monitoring for voriconazole associated adverse events is recommended if voriconazole is used sequentially after fluconazole.
Če vorikonazol uporabimo po uporabi flukonazola, je treba bolnika spremljati glede pojava z vorikonazolom povezanih neželenih učinkov.
You might be given this medicine by your doctor to treat the following types of fungal infections: - Cryptococcal meningitis- a fungal infection in the brain - Coccidioidomycosis- a disease of the bronchopulmonary system - Infections caused by Candida and found in the blood stream, body organs (e.g. heart, lungs) or urinary tract - Mucosal thrush - infection affecting the lining of the mouth, throat and denture sore mouth - Genital thrush - infection of the vagina or penis - Skin infections - e.g. athlete's foot, ringworm, jock itch, nail infection
pljuča) ali sečilih - Glivična okužba sluznice - okužba ustne sluznice, žrela in bolečina v ustih zaradi zobne proteze - Glivična okužba spolovil - okužba nožnice ali penisa - Okužbe kože - npr. glivice med prsti na nogah (atletsko stopalo), lišaj, srbenje v dimljah,
BEFORE YOU TAKE DIFLUCAN
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO DIFLUCAN
Rare side effects which affect 1 to 10 users in 10,000 are listed below: - lower than normal white blood cells that help defend against infections and blood cells that help to stop bleeding - red or purple discoloration of the skin which may be caused by low platelet count, other blood cell changes - blood chemistry changes (high blood levels of cholesterol, fats) - low blood potassium - shaking - abnormal electrocardiogram (ECG), change in heart rate or rhythm - liver failure - allergic reactions (sometimes severe), including widespread blistering rash and skin peeling,
- število belih krvnih celic, ki pomagajo pri obrambi proti okužbam, in krvnih celic, ki pomagajo pri zaustavljanju krvavitev, je manjše od normalnega - rdeča ali škrlatna obarvanost kože, kar je lahko posledica majhnega števila krvnih ploščic, spremembe pri drugih krvnih celicah - nizka koncentracija kalija v krvi - spremembe v kemijski sestavi krvi (visoke ravni holesterola in maščob v krvi) - tresavica
Hepatic failure (see section 4.4), hepatocellular necrosis (see section 4.4), hepatitis (see section 4.4), hepatocellular damage (see section
Odpoved delovanja jeter (glejte poglavje 4.4), nekroza jetrnih celic (glejte poglavje 4.4), hepatitis (glejte poglavje 4.4), poškodba jetrnih celic (glejte poglavje
100 mg to 200 mg daily or 200 mg 3 times per week.
- Kandidoza požiralnika 100 mg do 200 mg na dan ali 200 mg 3-krat na teden
Diflucan and associated names (see Annex I) 50 mg hard capsules Diflucan and associated names (see Annex I) 100 mg hard capsules Diflucan and associated names (see Annex I) 150 mg hard capsules Diflucan and associated names (see Annex I) 200 mg hard capsules [See Annex I - To be completed nationally]
Diflucan in povezana imena (glejte Prilogo I) 50 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 100 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 150 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 200 mg trde kapsule [glejte Prilogo I - izpolni država članica]
Each ml contains 2 mg of fluconazole.
En ml raztopine za infundiranje vsebuje 2 mg flukonazola.
Diflucan and associated names (see Annex 1) 50 mg hard capsules Diflucan and associated names (see Annex 1) 100 mg hard capsules Diflucan and associated names (see Annex 1) 150 mg hard capsules Diflucan and associated names (see Annex 1) 200 mg hard capsules [See Annex I - To be completed nationally]
Diflucan in povezana imena (glejte Prilogo I) 50 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 100 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 150 mg trde kapsule Diflucan in povezana imena (glejte Prilogo I) 200 mg trde kapsule
1 ml of reconstituted suspension contains 10 mg fluconazole.
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN En ml rekonstituirane suspenzije vsebuje 10 mg flukonazola.
Important information about some of the ingredients of Diflucan Diflucan contains sucrose (sugar).
Zdravilo Diflucan vsebuje saharozo (sladkor).
Diflucan oral solution contains sucrose.
Zdravilo Diflucan peroralna raztopina vsebuje saharozo.
Plasma protein binding is low
Vezava na beljakovine v plazmi je majhna (11-12 %).
Longer periods may be used in patients with severely compromised immune function.
Pri bolnikih z močno oslabelim delovanjem imunskega sistema lahko zdravljenje traja dlje časa.
NAME OF THE MARKETING AUTHORISATION HOLDER [See Annex I - To be completed nationally]
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM [glejte Prilogo I - izpolni država članica]
Fatigue, malaise, asthenia, fever
Utrujenost, splošno slabo počutje, astenija, zvišana telesna temperatura
- Each hard capsule contains fluconazole 150 mg. - The other ingredients are:
- Ena trda kapsula vsebuje 150 mg flukonazola.
This summary was last updated in 05-2010.
Povzetek je bil nazadnje posodobljen 05-2010.
A response is usually seen in two to four weeks.
Odziv se navadno opazi v dveh do štirih tednih.
• major depression;
• hudo depresivno motnjo;
The marketing authorisation holder is Eli Lilly Netherlands B.V.
Imetnik dovoljenja za promet je družba Eli Lilly Netherlands B.V.
The response to treatment should be assessed regularly.
Redno je treba ocenjevati odziv na zdravljenje.
The main measure of effectiveness was the change in the severity of pain each week.
Glavno merilo učinkovitosti je bila sprememba jakosti bolečine vsak teden.
Xeristar duloxetine
Xeristar duloksetin
The European Commission granted a marketing authorisation valid throughout the European Union for Xeristar on 17 December 2004.
Evropska komisija je dovoljenje za promet z zdravilom Xeristar, veljavno po vsej Evropski uniji, odobrila dne 17. decembra 2004.
Xeristar is used to treat adults (aged 18 years or over) with the following diseases:
Zdravilo Xeristar se uporablja za zdravljenje odraslih (starih 18 let ali več) z naslednjimi boleznimi:
In both studies, pain reduction was seen from the first week of treatment for up to 12 weeks.
V obeh študijah je bilo zmanjšanje bolečine opaziti od prvega tedna zdravljenja do 12 tednov.
Other information about Xeristar:
Druge informacije o zdravilu Xeristar:
Treatment must not be started in patients with uncontrolled hypertension (high blood pressure), because of a risk of hypertensive crisis (sudden, dangerously high blood pressure).
Zdravljenje se ne sme uvesti pri bolnikih z nenadzorovano hipertenzijo (visokim krvnim tlakom) zaradi tveganja hipertenzivne krize (nenadnega, nevarno visokega krvnega tlaka).
This document is a summary of the European Public Assessment Report (EPAR) for Xeristar.
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Xeristar.
Since these neurotransmitters are involved in maintaining high mood and reducing the sensation of pain, blocking their re-uptake into nerve cells can improve the symptoms of depression, anxiety and neuropathic pain.
Ker ti živčni prenašalci sodelujejo pri ohranjanju dobrega razpoloženja in zmanjševanju občutka bolečine, lahko zaviranje njihovega prevzema v živčne celice izboljša simptome depresije, anksioznosti in bolečine nevropatije.
The most common side effects with Xeristar (seen in more than 1 patient in 10) are nausea (feeling sick), headache, dry mouth, somnolence (sleepiness) and dizziness.
Najpogostejši neželeni učinki zdravila Xeristar (opaženi pri več kot 1 bolniku od 10) so navzeja (slabost), glavobol, suha usta, somnolenca (zaspanost) in omotica.
For more information about treatment with Xeristar, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Xeristar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
The CHMP decided that Xeristar's benefits are greater than its risks and recommended that it be given marketing authorisation.
CHMP je zaključil, da so koristi zdravila Xeristar večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
What benefit has Xeristar shown during the studies?
Kakšne koristi je zdravilo Xeristar izkazalo med študijami?
Four studies looked at the treatment of the disorder by measuring the reduction in symptoms after nine to 10 weeks.
V štirih študijah so proučevali zdravljenje motnje tako, da so ocenjevali zmanjšanje simptomov po devetih do desetih tednih.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Xeristar.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) zdravilo Xeristar ocenil, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Deluje tako, da preprečuje ponovno prevzemanje 5-hidroksitriptamina (imenovanega tudi serotonin) in noradrenalina v živčne celice možganov in hrbtenjače.
Any patients taking Xeristar who have distressing thoughts or experiences at any time should tell their doctor immediately.
Vsak bolnik, ki jemlje zdravilo Xeristar in opazi misli ali občutke, ki povzročajo stisko, mora o tem nemudoma obvestiti svojega zdravnika.
For generalised anxiety disorder, the recommended starting dose is 30 mg once a day, but the dose can be increased to 60, 90 or 120 mg depending on the patient's response.
Pri splošni anksiozni motnji znaša priporočeni začetni odmerek 30 mg enkrat na dan, vendar se lahko odmerek poveča na 60, 90 ali 120 mg glede na odziv bolnika.
Six of the studies looked at the treatment of depression and measured the change in symptoms over up to six months.
V šestih študijah so proučevali zdravljenje depresije in ocenjevali spremembo simptomov v obdobju šestih mesecev.
Xeristar must also not be used in patients with certain types of liver disease or patients with severe kidney disease.
Zdravilo Xeristar se prav tako ne sme uporabljati pri bolnikih z nekaterimi vrstami obolenj jeter ali bolnikih s hudimi obolenji ledvic.
Xeristar is a medicine that contains the active substance duloxetine.
Xeristar je zdravilo, ki vsebuje zdravilno učinkovino duloksetin.
Xeristar must not be used together with monoamine oxidase inhibitors (another group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotic).
Zdravilo Xeristar se ne sme uporabljati skupaj z zaviralci monoaminooksidaze (drugo skupino zdravil proti depresiji), fluvoksaminom (drugim zdravilom proti depresiji), ciprofloksacinom ali enoksacinom (vrstama antibiotikov).
As with other antidepressants, isolated cases of suicidal thoughts and behaviour have been seen in patients taking Xeristar, particularly in the first few weeks of treatment for depression.
Kot pri drugih zdravilih proti depresiji so tudi pri zdravilu Xeristar opazili posamezne primere samomorilnih misli in samomorilnega vedenja, še zlasti v prvih nekaj tednih zdravljenja depresije.
What is the risk associated with Xeristar?
Kakšna tveganja so povezana z zdravilom Xeristar?
Xeristar should not be used in people who may be hypersensitive (allergic) to duloxetine or any of the other ingredients.
Zdravila Xeristar ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) duloksetin ali katero koli drugo sestavino zdravila.
This prevents the active substance from being destroyed by the acid in the stomach.
Tako se prepreči, da bi želodčna kislina uničila zdravilno učinkovino.
The fifth study looked at how long it took for symptoms to return in 429 patients who had initially responded to Xeristar.
V peti študiji s 429 bolniki so proučevali, kako hitro se simptomi spet pojavijo pri bolnikih, ki so se sprva odzvali na zdravilo Xeristar.
Why has Xeristar been approved?
Zakaj je bilo zdravilo Xeristar odobreno?
For generalised anxiety disorder, Xeristar has been compared with placebo in five studies involving a total of 2,337 patients.
Pri splošni anksiozni motnji so zdravilo Xeristar primerjali s placebom v petih študijah, v katere je bilo skupno vključenih 2 337 bolnikov.
For major depression, the recommended dose of Xeristar is 60 mg once a day.
Pri zdravljenju hude depresije je priporočeni odmerek zdravila Xeristar 60 mg enkrat dnevno.
In patients who respond to Xeristar, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Za bolnike, ki se odzivajo na zdravilo Xeristar, je zdravljenje priporočljivo nadaljevati še nekaj mesecev, da se prepreči ponovni pojav bolezni, za bolnike, ki so v preteklosti imeli ponavljajoča se obdobja depresije, pa še dlje.
For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of 120 mg per day.
Pri zdravljenju bolečine diabetične nevropatije je priporočeni odmerek 60 mg na dan, nekateri bolniki pa bodo morda potrebovali višji odmerek, 120 mg na dan.
For the treatment of diabetic neuropathic pain, Xeristar was more effective at reducing pain than placebo.
Pri zdravljenju bolečine diabetične nevropatije je bilo zdravilo Xeristar pri zmanjševanju bolečine učinkovitejše od placeba.
The active substance in Xeristar, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Zdravilna učinkovina zdravila Xeristar, duloksetin, je zaviralec ponovnega prevzema serotonina in noradrenalina.
In the two studies where the approved dose of Xeristar was compared with placebo, Xeristar was more effective.
V dveh študijah, v katerih so odobreni odmerek zdravila Xeristar primerjali s placebom, se je zdravilo Xeristar izkazalo za učinkovitejše.
The dose of Xeristar should be reduced gradually when stopping treatment.
Ob prenehanju zdravljenja je treba odmerek zdravila Xeristar zmanjševati postopoma.
For the full list of all side effects reported with Xeristar, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Xeristar, glejte navodilo za uporabo.
Although the results of the depression studies varied, Xeristar was more effective than placebo in four of the studies.
Čeprav so se rezultati študij o depresiji med seboj razlikovali, je bilo zdravilo Xeristar v štirih študijah učinkovitejše od placeba.
For generalised anxiety disorder, Xeristar was also more effective than placebo at treating the disorder and preventing symptoms returning.
Pri splošni anksiozni motnji je bilo zdravilo Xeristar prav tako učinkovitejše od placeba pri preprečevanju ponovnega pojava simptomov.
For neuropathic pain, Xeristar has been compared with placebo in two 12-week studies in 809 diabetic adults.
Pri nevropatski bolečini so zdravilo Xeristar v 12-tedenski študiji z 809 sladkornimi bolniki primerjali s placebom.
The full EPAR for Xeristar can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Xeristar je na voljo tukaj.